FDA Grants Breakthrough Status to Novel Liver Cancer Blood Test

TAIPEI and CHINO, Calif. – April 21, 2026 – The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to CatCHimera, a groundbreaking liquid biopsy platform developed by TCM Biotech (TPEx: 4169). The test is designed to monitor for the recurrence of hepatocellular carcinoma (HCC), the most common type of liver cancer, by detecting a novel class of biomarkers in the blood. This designation signals a major step forward in addressing a critical 'blind spot' in cancer care, potentially offering a new standard for post-treatment surveillance in a disease notorious for its high recurrence rate.

Unlike most liquid biopsies that search for cancer-causing somatic mutations, CatCHimera employs a unique strategy. It identifies viral-host DNA (vh-DNA), genetic fragments created when the Hepatitis B virus (HBV) integrates its DNA into a patient’s liver cells—a primary driver of HCC. These integration points act as unique, stable fingerprints for each patient's tumor, allowing for highly specific and sensitive tracking of minimal residual disease (MRD) after surgery or other curative treatments.

The FDA’s Breakthrough Device Program is designed to expedite the review of medical devices that provide for more effective treatment or diagnosis of life-threatening diseases. For CatCHimera, this designation acknowledges its potential to fill a significant unmet need and could accelerate its path to clinical use, offering new hope to hundreds of thousands of patients worldwide.

Beyond Mutations: A New Biomarker for a Global Killer

The scientific innovation behind CatCHimera lies in its departure from conventional circulating tumor DNA (ctDNA) analysis. Most MRD tests rely on identifying a panel of somatic mutations—the genetic errors that drive cancer growth. However, this approach can be challenging in HCC, where tumor genetic profiles can be complex and heterogeneous.

CatCHimera circumvents this by targeting the literal footprint of the virus. Chronic HBV infection is a leading cause of HCC globally, and the integration of the viral genome into the host's DNA is a key oncogenic event. These HBV-host genome integration junctions are unique to a patient’s tumor clones. By sequencing a patient's tumor tissue once to identify these unique junctions, the CatCHimera test can then use a simple blood draw to specifically search for these markers post-treatment.

Developed in a close collaboration with the renowned research group of Academician Pei-Jer Chen at National Taiwan University, the platform leverages powerful capture-NGS (Next-Generation Sequencing) and ddPCR (droplet digital PCR) technologies. This combination enables the detection of vanishingly small amounts of tumor-derived DNA in the bloodstream, signaling a cancer recurrence long before it becomes visible on a scan.

Clinical data published in leading journals, including Hepatology and Cellular and Molecular Gastroenterology and Hepatology, underscore the platform's potential. Studies show the test can detect vh-DNA in 98% of pre-surgical plasma samples from HCC patients, even in tumors as small as 1.5 cm.

Closing the Surveillance Gap in Liver Cancer Care

Hepatocellular carcinoma remains one of the deadliest cancers worldwide, ranking as the third leading cause of cancer-related death. Despite curative treatments like surgical resection, the five-year recurrence rate is over 50%, a grim statistic that has created an urgent need for better monitoring tools.

The current standard of care involves regular imaging with CT or MRI scans and blood tests for the biomarker alpha-fetoprotein (AFP). While useful, these methods often detect recurrence only after a new tumor has grown to a significant size, limiting treatment options. CatCHimera's performance in clinical studies suggests it can dramatically outperform this standard.

Most notably, the test demonstrated a mean lead time of 158 days over conventional CT imaging in detecting recurrence. This five-month head start could be transformative for patient outcomes, providing a critical window for physicians to intervene with treatments when the cancer burden is lowest and more manageable. The test also showed a high negative predictive value (NPV) of 92%, giving patients and doctors greater confidence that a negative result truly means no evidence of disease.

Furthermore, when combined with existing biomarkers AFP and PIVKA-II, the platform achieved an impressive 95.8% sensitivity and 95.5% specificity. Its sensitivity was found to be superior to AFP alone, particularly for tumors smaller than 5 cm, a common challenge in early detection. This enhanced performance promises to refine patient monitoring, reduce anxiety from ambiguous scan results, and guide more timely and effective clinical decisions.

A Strategic Milestone for a Growing Market

For TCM Biotech, a publicly traded company with operations in Taiwan and California, the FDA Breakthrough Designation is more than a regulatory milestone; it is a key pillar of its commercialization strategy. The designation provides a prioritized review pathway and more collaborative engagement with the FDA, which can significantly shorten the timeline to market access in the United States. This U.S. validation is also expected to facilitate technology licensing and regulatory approvals in other key markets, including China and Europe, where the company has already secured patents.

Unlike many early-stage biotech firms, TCM Biotech is a profitable entity with established distribution channels, giving it a solid foundation to support the launch and scaling of a new diagnostic. The company is targeting a vast and underserved market. With approximately 296 million chronic HBV carriers and over 450,000 new liver cancer diagnoses annually, the addressable population is immense.

While CatCHimera is the first ctDNA MRD platform to receive Breakthrough Designation for liver cancer, the liquid biopsy field is intensely competitive. However, its unique biomarker approach provides a strong competitive moat, particularly in the HBV-endemic regions of Asia and other parts of the world. The primary limitation is that its utility is focused on the majority of HCC cases linked to HBV, not those arising from other causes like Hepatitis C or fatty liver disease. Nonetheless, by focusing on this large, well-defined patient population, TCM Biotech is poised to become a significant player in the precision oncology diagnostics space for a long-neglected disease.